• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
171300 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
! a3 s5 J5 b/ k& z# `0 d" `' \$ N+ u2 _$ u8 x
# N  f! \! j* O) c
Sub-category:3 m" B, {7 M9 X' ?- j1 }) D9 U
Molecular Targets 2 p9 a& F3 L# L

  U0 Q) g0 f3 p! z, g3 o2 m1 X7 `+ Q! K) I+ U2 R1 Q9 |" m
Category:
* }" Z/ _8 K" Y  [2 \# t8 JTumor Biology ( Y1 O% M: o; u
( a+ ~; _7 Y8 D" }" {4 n9 y1 e

0 O! a5 O3 ], x  GMeeting:
8 q  ^; r2 H( k2011 ASCO Annual Meeting - C8 s. k# T1 U0 ]

+ B+ o2 _% J1 e" B2 v/ Z9 O: }& w8 J7 R: @2 d! ~! K
Session Type and Session Title:
! {3 Y5 c( ?# [5 _  ^Poster Discussion Session, Tumor Biology
+ O9 p  f0 p5 T* h6 H  _
1 W0 r' A& G7 J4 h5 a- V
  V" O5 M8 v& u6 iAbstract No:
6 r9 u$ T* {3 @& e9 x# D2 n10517 4 |2 s) V+ \, E1 r' G
& {: d, N  T/ }, ]! \

# h) h( L7 c3 o1 {9 S5 QCitation:
9 v: \* u+ f2 G6 Z: cJ Clin Oncol 29: 2011 (suppl; abstr 10517)
- C1 Y# m5 W- {- ]  l$ u* f) _/ X! c
$ M: ~  o) T* U3 C; T( z9 ?8 _7 j2 b6 I
Author(s):0 j+ m7 z: u3 _5 ], k/ J4 {7 Z
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China & @" U- S# a- |3 U* Z/ E0 `* l

$ a- H7 n/ H. h& ?& t* k7 I. {3 `8 c! d' u
: v  X% t+ }. H  B6 A
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
( {2 F2 o. a8 @( e( A
$ t8 ?, ]5 A- GAbstract Disclosures
/ q- p* v: a9 h- C+ F- |+ {- v
! B# e8 X( I$ L- p! a4 C4 nAbstract:
* z# g$ |- k$ ^# z# _2 f( k2 D
/ g. t; C* ^8 S: h1 f" t2 R' a
: ^0 w& B6 }8 G& g  x7 L' \: m7 n7 T+ DBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.0 m+ c7 O( d2 [* g

' l+ u$ G. O3 M$ E! w# {$ M: W ' V) W) Y3 E9 C. Y
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
8 R# Q* U2 i* |6 U% W! s2 {: {没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

% N; D5 ]- r% `7 f3 r. m  [8 i# O3 u化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
: \* ?. H9 o2 ~. T3 U4 K易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。; |9 T9 {% [8 {) x- F% Z8 Q5 x
ALK一个指标医院要900多 ...

! R' w0 ~  O8 v" Q平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?1 E* }( R; O) {
  ?- s6 L0 H1 T4 d8 C* P! B6 j
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表